It can inhibit K-Ras in both its active (GTP-bound) and inactive (GDP-bound) states, potentially offering a way to bypass resistance mechanisms seen in earlier-generation inhibitors like ARS-1620. 3. The Future of Mid-Size Peptides The development of KS-58 highlights a shift toward mid-size peptides
The ASBT (SLC10A2) is the primary mechanism for the enterohepatic circulation of bile acids. KBI-058 acts locally within the ileum to: KBI-058
It’s exhausting just to look at it.